Content by Moderna, Inc.
|4 min read
COVID-19 Vaccine Phase 2/3 Study in Children Successfully Met Primary Endpoint
Two 25 μg doses of mRNA-1273 in participants six months to under six years met primary endpoint
|2 min read
Phase 3 Portion of Pivotal Trial for mRNA RSV Vaccine Candidate
RSV causes severe disease burden among older adults and young children; there is no approved vaccine to prevent RSV
|2 min read
Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine Spikevax
SPIKEVAX has received approval by regulators in more than 70 countries
|2 min read
Moderna Announces Additional 20 Million Doses of COVID-19 Vaccine
New 2022 supply agreement: 20 million additional doses purchased for supply in Q2 for total of 136.5 million doses
|3 min read
Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
Company testing three existing COVID-19 vaccine booster candidates against the Omicron variant
|2 min read
Booster Dose of COVID-19 Vaccine in the US for Adults 18 Years and Older
Authorization includes the use of Moderna’s booster dose following primary vaccination with other authorized vaccines
|2 min read
Data from Phase 2/3 Study of COVID-19 Vaccine in Children Ages Six to 11
Two 50 μg doses of mRNA-1273 were generally well tolerated and showed robust neutralizing antibody titers
|2 min read
FDA Authorization of a Booster Dose of Moderna’s COVID-19 Vaccine in the US
EUA granted for individuals 65 years of age and older, individuals ages 18 through 64 within certain high-risk groups
|1 min read
FDA Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals
A third dose of the Moderna COVID-19 vaccine may enhance immune response in immunocompromised populations
|2 min read
New Study Shows COVID-19 Vaccine Protects against Variants of Concern
Majority of participants who received primary series maintain functional antibodies against variants for six months
|3 min read
FDA Approves Emergency Use Authorization for Moderna's Coronavirus Vaccine
The US FDA Advisory Committee voted unanimously to approve emergency use of Moderna’s COVID-19 vaccinePage 1 of 1
